These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37987318)

  • 1. Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience.
    Rener K; Anžej Doma S; Fink M; Podgornik H; Preložnik Zupan I
    Hematol Rep; 2023 Nov; 15(4):597-607. PubMed ID: 37987318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
    Kruse-Jarres R; Peyvandi F; Oldenburg J; Chang T; Chebon S; Doral MY; Croteau SE; Lambert T; Kempton CL; Pipe SW; Ko RH; Trzaskoma B; Dhalluin C; Bienz NS; Niggli M; Lehle M; Paz-Priel I; Young G; Jiménez-Yuste V
    Blood Adv; 2022 Dec; 6(24):6140-6150. PubMed ID: 35939785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.
    Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V
    TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
    Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
    Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center.
    Cohen O; Levy-Mendelovich S; Budnik I; Ludan N; Lyskov SK; Livnat T; Avishai E; Efros O; Lubetsky A; Lalezari S; Misgav M; Brutman-Barazani T; Kenet G; Barg AA
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102178. PubMed ID: 37876894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peri-operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis.
    Yagyuu T; Furukawa S; Zaizen M; Yata S; Imada M; Nogami K; Kirita T
    Haemophilia; 2023 Jan; 29(1):172-179. PubMed ID: 36163647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience.
    Castaman G; Linari S; Pieri L; Carulli C; Prosperi P; Tonelli P; Demartis F; Fjerza R; Attanasio M; Coppo M; Salvianti F
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
    Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
    J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
    Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
    Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
    Escobar M; Agrawal N; Chatterjee S; Bhattacharya S; Caicedo J; Bullano M; Schultz BG
    J Med Econ; 2023; 26(1):574-580. PubMed ID: 36989380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis.
    Shimonishi N; Sasai K; Ogiwara K; Furukawa S; Nakajima Y; Mizumachi K; Yada K; Takeyama M; Shima M; Mizuno N; Nogami K
    Int J Hematol; 2023 Dec; 118(6):690-698. PubMed ID: 37803190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
    Kiialainen A; Niggli M; Kempton CL; Castaman G; Chang T; Paz-Priel I; Adamkewicz JI; Levy GG
    Haemophilia; 2022 Nov; 28(6):1033-1043. PubMed ID: 35905294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations.
    Yada K; Nogami K
    J Blood Med; 2019; 10():171-181. PubMed ID: 31308776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors.
    Hassan E; Jonathan L; Jayashree M
    Haemophilia; 2021 Nov; 27(6):e698-e703. PubMed ID: 34628693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors.
    Escobar M; Bullano M; Mokdad AG; Caicedo J; Schultz BG; Fan Q; Verma S
    Expert Rev Hematol; 2023 Jun; 16(6):467-474. PubMed ID: 37114481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.
    Linari S; Castaman G
    Ther Clin Risk Manag; 2020; 16():461-469. PubMed ID: 32547043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.